secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2026-05-15T20:13:34+00:00
Accession:  0001193125-26-226751
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel reports 39% improvement in prostate cancer-specific DFS with aglatimagene in phase 3 extended follow-up
--------------------------------------------------------------------------------

- Prostate cancer-specific DFS improved 39% vs placebo (HR 0.61, p=0.0031) at median 58-month follow-up.
- Consistent favorable trends in TTBF, TTM, metastasis rate, and TTNT in ITT population.
- In intermediate-risk subgroup (85% of patients), 90% reduction in time to metastasis (HR 0.1).
- Company plans to submit BLA to FDA in Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000119312526226751/0001193125-26-226751-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000119312526226751/d106447d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-226751

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer